Nascent Biotech Inc. (NBIO)

[RNsidersbuying]

$26B that's alot leftover for "vaccine research, distribution, and use" when considering the fed has only doled out probably less than $5B so far...

Also, sure would be nice to have some kind of timeframe as to when we might hear results from the tests in today's pr:

Patteson will test the hypothesis on mouse embryo fibroblast cells and lung airway epithelial cells to determine if the antibody will block the uptake of SARS2. Using a cell in which vimentin has been knocked out, the results will provide an important control of Pritumumab effects.

Nascent Biotech Chief Medical Officer over Viral Research, Dr. Navpaul Singh said, "This collaboration will determine if Pritumumab can effectively block SARS2 in an animal mouse model. It will also gauge Pritumumab's ability to bind vimentin in a live model."